Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

Clinical Trial Description

Males with a clinical diagnosis of X-linked retinitis pigmentosa (XLRP) caused by RPGR-ORF15 mutations will be asked to provide informed consent and will have a single blood or saliva sample obtained for DNA sequence analysis of genes known to cause XLRP, including the RPGR-ORF15 gene. All participants will be informed of the results of testing for these mutations. Those with qualifying mutations in the RPGR-ORF15 gene will be evaluated every 6 months for 3 years using a variety of non-invasive visual function tests to more fully characterize their clinical condition. Testing will include routine ophthalmic examinations and tests of visual acuity, perimetry, OCT, fundus imaging, and completion of quality of life questionnaires. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03314207
Study type	Observational
Source	Applied Genetic Technologies Corp
Contact
Status	Completed
Phase
Start date	December 1, 2017
Completion date	February 10, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04926129` - Natural History of the Progression of X-Linked Retinitis Pigmentosa
Recruiting	`NCT05926583` - A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa	Phase 3
Enrolling by invitation	`NCT06275620` - A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)	Phase 2
Completed	`NCT03116113` - A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112	Phase 1/Phase 2
Recruiting	`NCT04850118` - A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP	Phase 2/Phase 3
Active, not recruiting	`NCT04517149` - 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)	Phase 1/Phase 2
Enrolling by invitation	`NCT03584165` - Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa	Phase 3
Active, not recruiting	`NCT04312672` - Long-term Follow-up Gene Therapy Study for RPGR- XLRP
Completed	`NCT04868916` - An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa
Completed	`NCT03252847` - Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)	Phase 1/Phase 2
Recruiting	`NCT05874310` - Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa	Early Phase 1
Active, not recruiting	`NCT04671433` - Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	Phase 3
Active, not recruiting	`NCT04794101` - Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene	Phase 3
Active, not recruiting	`NCT03316560` - Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations	Phase 1/Phase 2
Active, not recruiting	`NCT06333249` - A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)	Phase 2